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ABSTRACT: Pheochromocytomas can have a highly variable presenta-
tion, making diagnosis challenging. To think of the tumor represents the
crucial initial step, but establishing the diagnosis requires biochemical
evidence of excessive catecholamine production and imaging studies to
localize the source. Currently, however, there exist no generally agreed
upon guidelines based on which tests and testing algorithms should be
used to confirm and locate or exclude a suspected pheochromocytoma.
Choice of biochemical tests and imaging studies instead usually depends
on institutional experience. At the First International Symposium on
Pheochromocytoma (ISP2005), held in Bethesda in October 2005, a panel
of experts and patient representatives discussed current problems and
available options for tumor diagnosis and localization and formulated
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recommendations, which were subsequently agreed upon by those in
attendance at the meeting. This article summarizes the discussion and
recommendations derived from that session.
KEYWORDS: pheochromocytoma; biochemical diagnosis; metaneph-
rines; catecholamines; localization; computed tomography; magnetic
resonance imaging; MIBG; positron emission tomography
INTRODUCTION
Pheochromocytomas, although a rare cause of hypertension, are dangerous
but usually surgically curable tumors that require consideration among large
numbers of patients, at considerable cost to healthcare systems. Among overall
numbers of patients tested for pheochromocytoma, less than 1% actually harbor
the tumor, but, based on autopsy studies, probably as many cases or more are
missed than are diagnosed.1–3 Thus, although frequently searched for and rarely
found, the tumor remains an overlooked clinical entity.
As discussed by Dr. William Manger (New York University Medical Center,
New York) in the keynote address at the First International Symposium on
Pheochromocytoma (ISP2005), diagnosis of the tumor first requires recogni-
tion of the varied clinical conditions and situations where pheochromocytoma
should be considered. To consider the possibility of the tumor represents the
crucial initial step, but confirming the diagnosis requires biochemical measure-
ments of catecholamines and catecholamine metabolites in urine or plasma,
followed by imaging studies to localize the source preparatory to surgical
removal.
A major problem in reaching or excluding the diagnosis of pheochromocy-
toma is that there are no generally agreed upon guidelines about how and which
biochemical tests and imaging studies should best be carried out, interpreted,
and followed-up. Practices vary among different centers, and recommenda-
tions are more often based on institutional experience than on evidence-based
medicine. Representatives of patient support groups at ISP2005 also indicated
that there was a need for improved education of clinicians in how to recognize,
diagnose, and localize the tumor, and they expressed frustration that progress
seemed hampered by lack of agreement and conflicting views from experts in
the field.
A “breakout session” was therefore held during ISP2005 with the aim of
fostering resolution of issues and problems associated with biochemical di-
agnosis and localization of pheochromocytoma. More than 40 participants,
including leading experts in the field and representatives from patient support
groups, attended the session. Under the guidance of impartial moderators (Dr.
Ashley Grossman, St Bartholomew’s Hospital, London, UK, and Dr. Hendrik
Lehnert, University of Warwick, UK), participants were asked to formulate
recommendations that were subsequently discussed and agreed upon at a
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final general session of this symposium where all attendees could be present.
Recommendations were based on answers to a series of questions, as detailed
below.
• What are the preferred biochemical tests or testing algorithms for con-
firming or excluding pheochromocytoma and what cost–benefit factors
should be considered?
• What precautions should be considered to minimize or avoid false-
positive results or drug interference during biochemical testing and imag-
ing procedures?
• What evidence for the presence of a tumor justifies imaging studies?
• What imaging strategies are appropriate for localization of pheochromo-
cytoma and in what order should they be applied?
This report reviews the discussion held at the breakout session, where possi-
ble outlines generally agreed upon recommendations, and where not possible
seeks to account for why there may be no clear answer and what future advances
may assist in reaching an answer. Because the presentation of pheochromocy-
toma can be variable and complex,4 which exerts a subsequent impact on the
choice of biochemical tests and imaging strategies, outlined recommendations
are not intended as strict guidelines, but as complements to sound clinical
judgment.
BIOCHEMICAL DIAGNOSIS
An important recommendation agreed upon by all attending participants at
the breakout and final discussion sessions of ISP2005 was that initial biochem-
ical testing for pheochromocytoma should include measurements of plasma
concentrations or urinary excretion of fractionated metanephrines (separate
measurements of normetanephrine and metanephrine) wherever these tests are
available. Importantly, this recommendation does not exclude the additional
use of other tests (e.g., urinary or plasma catecholamines) or measurements
of both plasma and urinary fractionated metanephrines during initial testing
for the tumor. Whereas other tests are used during initial testing, these should
be used in conjunction with measurements of fractionated metanephrines in
plasma or urine.
The importance of measurements of urinary or plasma fractionated
metanephrines for the diagnosis of pheochromocytoma is principally based
on research by National Institutes of Health (NIH) investigators establishing
that pheochromocytomas contain catechol-O-methyltransferase, the presence
of which results in the metabolism of catecholamines to metanephrines within
tumor cells.5–7 It is further proposed that production of metanephrines within
tumor cells is continuous and more accurately reflects tumor mass than release
of catecholamines, which can occur episodically or not at all in nonsecretory
tumors. Consistent with these concepts, it has now been established by four
independent groups of investigators that measurements of plasma
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TABLE 1. Sensitivity and specificity of measurements of plasma fractionated
metanephrines for diagnosis of pheochromocytoma
Diagnostic
Study Cohort (n) URL (nmol/L) Performance
Center Pheo No pheo NMN MN Sensitivity Specificity
Vienna9 17 14 0.66 0.31 100% 100%
NIH10 214 644 0.61 0.31 99% 89%
2.19 1.20 79%a 100%
Mayo Clinic12 56 445 0.90 0.50 96% 85%
University of Essen13 24 126 0.69 0.19 96% 80%
Freeman Hospitalb 11 114 0.90 0.55 100% 91%
Cleveland Clinicc 32 0 0.90 0.50 97% —
2.19 1.20 84%a —
All centers 354 1,343 98% 87%
URL = upper reference limits of reference intervals; NMN = normetanephrine; MN =
metanephrine.
aDenotes values of diagnostic sensitivity calculated using upper reference limits adjusted to provide
100% specificity; indicates percentage of patients where there is close to 100% probability of a
pheochromocytoma.
bPeaston, R.T., Neely, R.D.G. 2005. Biochemical diagnosis of pheochromocytoma: the role of
plasma metanephrines. Proceedings of the First International Symposium on Pheochromocytoma
[abstract]. 150.
cBravo, E.L., Bravo, T. 2005. Clinical characteristics of incidentally discovered pheochromocytoma
from an analysis of 50 proven cases. Proceedings of the First International Symposium on Pheochro-
mocytoma [abstract] 27. This volume.
metanephrines provides superior diagnostic sensitivity over measurements of
plasma or urinary catecholamines for the detection of pheochromocytoma.8–13
A further study presented at ISP2005 by Dr. Robert Peaston (Freeman Hos-
pital, Newcastle upon Tyne, UK) provided documentation by a fifth group
that measurements of plasma metanephrines provide improved accuracy over
urinary catecholamines for the diagnosis of the tumor (TABLE 1).
Several studies involving measurements of urinary fractionated
metanephrines have similarly indicated that these tests provide superior
diagnostic sensitivity over urinary or plasma catecholamines, urinary vanillyl-
mandelic acid, or total metanephrines, the latter measured as the combined
sum of normetanephrine and metanephrine by early spectrophotometric
methods.10,14–17 Taken together, the weight of accumulating evidence clearly
indicates that measurements of fractionated metanephrines in urine or plasma
provide superior diagnostic sensitivity over urinary or plasma measurements
of catecholamines and other catecholamine metabolites.
There was no consensus at the meeting as to whether measurements of
plasma or urinary fractionated metanephrines offer the preferred test, although
evidence by two different groups has indicated that the plasma test may of-
fer diagnostic advantages over the urine test.10,13 Against this, Dr. Emmanuel
Bravo (Cleveland Clinic, OH) presented evidence at ISP2005 that measure-
ments of urinary fractionated metanephrines were superior to plasma-free
336 ANNALS NEW YORK ACADEMY OF SCIENCES
TABLE 2. Relative merits and demerits of measurements of urinary fractionated and
plasma-free metanephrines for the diagnosis of pheochromocytoma
Urinary Fractionated Metanephrines Plasma-Free Metanephrines
Well-established, widely available test Relatively new test with limited availability
Urinary concentrations (200–2,000 nmol)
make analysis relatively easy
Plasma concentrations (0.1–0.5 nmol) can
make analysis difficult
Easy for clinicians to implement with
minimal expenditure of time and effort
Blood collections require some time and
effort by medical staff
Twenty-four-hour collections can be
inconvenient for patients
Blood sampling relatively more convenient
for patients
Problems with reliability of incomplete
timed urine collections
Collection and handling of blood samples
can be better regulated
Difficult to control dietary and daily life
influences on sympathoadrenal function
Influences of diet and sympathoadrenal
function more easily controlled
In children 24-h collections are difficult
and results are difficult to interpret
without age-appropriate reference
intervals
In children blood sampling may be
stressful, but results are more easily
interpreted without age-appropriate
reference intervals
Urine collections may be inappropriate in
patients with renal failure
Test is applicable in patients with renal
failure
metanephrines for the diagnosis of incidentally discovered pheochromocy-
tomas; the urinary test returned positive results in 96% of patients with the
tumor compared to 84% for the plasma test. The latter value, however, was
obtained using upper limits of reference intervals identical to those described
elsewhere that had been adjusted to provide 100% specificity.10 Thus, the re-
sults of the study by Bravo may be reinterpreted to indicate that 84% of the
patients with pheochromocytoma had elevations of plasma metanephrines of
sufficiently high magnitude to provide close to 100% probability of a tumor.
When results were re-examined using the appropriate laboratory-derived ref-
erence intervals, diagnostic sensitivity was 97% (TABLE 1).
Any differences in overall diagnostic accuracy of plasma compared to uri-
nary fractionated metanephrines are probably relatively small compared to
differences of either test of metanephrines with tests of plasma or urinary cat-
echolamines. Choice of either plasma or urinary fractionated metanephrines
may benefit from consideration of additional factors as outlined in TABLE 2.
Dr. Anna Sawka (University of Toronto, Toronto, Canada), who described
the experience of investigators at the Mayo Clinic in the diagnosis of pheochro-
mocytoma, contended that while plasma measurements of metanephrines of-
fered high diagnostic sensitivity, the test was not widely available and has
lower specificity compared with some other tests, which has a negative impact
on cost-effectiveness.18 Dr. Karel Pacak (NIH, Bethesda, MD) countered that
cost–benefit projections should take into account the potential costs of missing
the diagnosis due to use of tests with inadequate sensitivity.
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It was further indicated by Dr. Graeme Eisenhofer (NIH, Bethesda, MD) that
because missing a pheochromocytoma can have deadly consequences, one of
the most important considerations in the choice of initial test is a high level of
reliability that the test will provide a positive result in that rare patient with the
tumor. In other words, the initial screening test should be of very high sensi-
tivity. This conversely also provides confidence that a negative result reliably
excludes the tumor, thus avoiding the need for multiple or repeat biochemical
testing or even costly and unnecessary imaging studies to rule out the tumor,
aspects that also should be considered in any cost–benefit analysis. There was
general agreement with the conclusions reached by Dr. Sawka in her decision
analysis that it was not cost-effective to screen all hypertensives for pheochro-
mocytoma, at least using currently available biochemical tests. In contrast, for
individuals genetically predisposed to syndromic pheochromocytoma or iden-
tified with an adrenal incidentaloma, the risk or pretest probability of disease
is so high that biochemical testing is usually warranted for all such patients.
It was recognized that while measurements of plasma or urinary
metanephrines may fail to detect some tumors that synthesize only small
amounts of catecholamines or exclusively dopamine, patients with such tu-
mors have an atypical clinical presentation that can benefit from consid-
eration of other testing strategies. As originally established by Dr. Morris
Brown (University of Cambridge, Cambridge, UK), present at the breakout
session, urinary dopamine is mainly derived from renal extraction of circu-
lating dihydroxyphenylalanine and local conversion to dopamine by aromatic
amino-acid decarboxylase.19 Thus, measurements of plasma dopamine or its
O-methylated metabolite, methoxytyramine (which may be measured in uri-
nary and plasma assays of metanephrines), provide better methods for detect-
ing dopamine-producing tumors than measurements of urinary dopamine.20
In general, though, it should be emphasized that in any test the sensitivity and
specificity are inter-related, and dependent on reference intervals. Assessment
of diagnostic efficacy is therefore most appropriately achieved by combined
examination of sensitivity and specificity in a given clinical context.
A second recommendation arising from the discussions related to the above
considerations at the breakout session was that reference intervals for initial
tests of urinary or plasma-fractionated metanephrines should be established
primarily to ensure optimum diagnostic sensitivity, with specificity being a
secondary consideration. Suboptimal diagnostic specificity was nevertheless
agreed to present a significant problem. To address the problem of false-
positive results, it was further recommended that testing algorithms should not
simply rely on a binary approach for test interpretation (i.e., consideration of
whether a test yields a positive or negative result), but should take advantage of
the continuous nature of biochemical test results (FIG. 1). For example, while
a single elevation of urinary or plasma normetanephrine slightly above the
upper reference intervals may only marginally increase the pre- to post-test
probability of pheochromocytoma, an elevation of more than fourfold above
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FIGURE 1. The binary versus continuous approach for the interpretation of biochemi-
cal test results is illustrated using measurements of plasma normetanephrine. The horizontal
dashed line in both panels illustrates the upper reference limits (0.61 nmol/L) used to deter-
mine whether a plasma concentration of normetanephrine is normal or elevated (negative
vs. positive test results according to the binary approach). With some exceptions, noted
as follows, pheochromocytoma may be excluded when plasma levels of normetanephrine
fall below that level. Exceptions where plasma values in patients with pheochromocytoma
fall below the upper reference limit include patients with isolated elevations of plasma
metanephrine (metabolite of epinephrine) or methoxytyramine (metabolite of dopamine)
or patients with small or microscopic tumors and no other biochemical evidence or signs
or symptoms of catecholamine excess. The horizontal dotted line in the panel on the right
illustrates the level of plasma normetanephrine (2.19 nmol/L) above which the test provides
100% diagnostic specificity. Results that are situated between the two levels (gray area)
indicate a tumor is possible, with the probability increasing the higher the value of the test
result. Levels above 2.19 nmol/L provide close to 100% probability of a tumor.
these intervals is associated with close to 100% probability of the tumor. In
the latter situation more emphasis may be placed on immediately locating the
tumor, whereas in the former situation involving test results in the “gray area,”
there is more of a need to first exclude a false-positive result. Again, some idea
of the diagnostic overlap that is seen in weighing sensitivity against specificity
is shown by the results in FIGURE 1.
The above recommendations followed lengthy discussion at the breakout
session centering on reference intervals, and this was clearly contingent upon
the form of sample collection and the appropriate methods for blood sam-
pling. Ms. Debra Harlander (Camden, NY), representing the Pheochromo-
cytoma Support Group, outlined how highly variable instructions for blood
sampling from various laboratories and institutions were causing confusion
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among patients and clinicians. At some centers blood sampling was done af-
ter 20 min of supine rest using an indwelling i.v. cannula with patients fasting
and avoiding acetaminophen (paracetamol). In contrast, elsewhere instructions
were inconsistent, with sampling usually carried out with patients seated.
The issue of seated versus supine blood sampling was addressed by Jacques
Lenders (St. Radboud University Hospital, Nimegen, the Netherlands), who
presented evidence at ISP2005 that blood sampling in the seated position re-
sulted in 25–30% increases in plasma metanephrines compared to sampling
after 20 min of supine rest. It was further shown that use of reference intervals
established from blood samples collected in the seated position resulted in
reduced diagnostic sensitivity, while testing for pheochromocytoma in seated
patients using reference intervals established from samples collected in the
supine position substantially reduced diagnostic specificity. It was therefore
agreed by all present that reference intervals for plasma free metanephrines
should be established using samples collected with the patient in the supine
position. To minimize false-positive results, it was further recommended that
blood samples for the diagnosis of pheochromocytoma should ideally be col-
lected after 20 min of supine rest. A caveat to this recommendation was the
recognition that blood sampling is usually done by phlebotomists licensed to
carry out the procedure according to specific practices. It was therefore pro-
posed that where blood sampling in the seated position returns positive results
in the “gray area,” repeat testing should be carried out with blood samples col-
lected after 20 min of supine rest, and where necessary carried out by clinical
staff not subject to the same restrictions as phlebotomy technicians.
The use of appropriate normotensive versus hypertensive reference popula-
tions,21 including (as pointed out by Dr. Sawka) requirements for age adjust-
ments,22 and by Dr. Eisenhofer, gender influences,23 represented other issues
touched upon during the breakout session that may assist in interpretation of
biochemical tests of catecholamine excess. Taking into account such variables,
together with the continuous nature of test results, to calculate changes in pre-
to post-test probabilities of disease for individual patients may be facilitated
by advances in test reporting to provide improved approaches to guide clini-
cal decision making for the future. Irrespective of such advances, difficulties
in distinguishing true- from false-positive results for tests of catecholamine
excess will almost certainly persist, particularly when emphasis is placed on
diagnostic sensitivity over specificity.
There was general agreement at the breakout session that imaging studies
to search for a suspected tumor should usually not be initiated until biochem-
ical or other evidence of a pheochromocytoma is reasonably compelling. The
possibility of false-positive biochemical test results should first be consid-
ered and wherever possible excluded. Medications represent common causes
of false-positive results, either through direct analytical interference with
techniques used to measure catecholamines and catecholamine metabolites,
or through pharmacological influences on actual plasma or urinary levels.
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The former causes tend to be method-specific and vary from laboratory to
laboratory, making general recommendations on what medications to avoid
largely inappropriate. Among the latter causes, tricyclic antidepressants and
the -adrenoceptor blocker, phenoxybenzamine, were described in one study
as responsible for close to 50% of all false-positive elevations of plasma and
urinary norepinephrine and normetanephrine.24 Repeat testing after discon-
tinuation of suspect medications can be used to exclude these as causes of
false-positive results. Use of confirmatory follow-up tests, such as urinary
fractionated metanephrines to support patterns of increases in initial mea-
surements of plasma metanephrines, or vice versa, were outlined as other ap-
proaches to exclude false-positive results, particularly where there is concern
about analytical validity.
In all approaches involving multiple tests of catecholamine excess, due con-
sideration should also be given to the inter-dependence of the various analytes
that may compromise Bayesian approaches to clinical decision making. A
false-positive elevation of urinary normetanephrine due to sympathetic activa-
tion is also likely to be associated with false-positive elevations of urinary and
plasma norepinephrine and plasma normetanephrine. Thus, while elevations
in the latter analytes measured in follow-up tests may serve to confirm the va-
lidity of the initial elevated urinary normetanephrine, those additional positive
test results do not always provide increased evidence of a pheochromocytoma
any more than they provide increased evidence for sympathetic activation. In
such situations suppression tests using clonidine or pentolinium can be useful
for distinguishing true-positive results due to a pheochromocytoma from false-
positive results due to sympathetic activation.25,26 Such tests, although origi-
nally developed to distinguish true- from false-positive elevations of plasma
catecholamines, may also be applied to distinguish true- from false-positive
elevations of urinary metanephrines27 or plasma normetanephrine.24
TUMOR LOCALIZATION
Several recent advances in our understanding of pheochromocytoma are
now important for physicians to consider when deciding on which imag-
ing modality to use for localization of pheochromocytoma. As outlined at
ISP2005 by Dr. Hartmut Neumann (University of Freiburg, Freiburg, Ger-
many) and Dr. Anne-Paule Gimenez-Roqueplo (Université Paris-Descartes,
Paris, France), between 12% and 24% of patients with apparently sporadic
pheochromocytoma may in fact be carriers of germline mutations, indi-
cating hereditary disease with a predisposition for bilateral adrenal, extra-
adrenal, or multiple tumors.28,29 Malignant pheochromocytoma, although
rare in multiple endocrine neoplasia type 2 (MEN 2) and von Hippel-
Lindau (VHL) syndrome, is common in patients with succinate dehydroge-
nase B (SDHB) mutations, and is present in about 10% of patients overall at
GROSSMAN et al.: BIOCHEMICAL DIAGNOSIS AND LOCALIZATION 341
presentation.29–31 Further, as outlined at the meeting by Dr. Pierre-François
Plouin (Université Paris-Descartes, Paris, France), about 11% of pheochromo-
cytomas recur as malignant disease. Furthermore, improved biochemical diag-
nosis of pheochromocytoma requires imaging techniques to locate increasingly
smaller tumors (often around 1 cm in size). In addition, the more frequent use
of imaging techniques is leading to increased recognition of “adrenal inciden-
talomas” as an important clinical finding, requiring follow-up to distinguish
functional tumors (e.g., pheochromocytomas) from the more common benign
cortical adenomas.32,33 Well-defined biochemical phenotypes of adrenal ver-
sus extra-adrenal pheochromocytomas and relationships of biochemical find-
ings with tumor mass may further help guide the proper use of anatomical and
functional imaging studies.34
Below are outlined some of the more important considerations and recom-
mendations on the use of anatomical and functional imaging studies (including
their advantages and disadvantages) as discussed during the breakout session.
Careful selection of imaging studies should decrease costs and radiation ex-
posure, as well as time and effort required for correct diagnostic localization
of tumors.
Anatomical Imaging Studies
In general, participants felt strongly that localization of pheochromocytoma
should only be initiated once the clinical evidence for the tumor is reasonably
compelling. For most patients when initial suspicion is based on signs and
symptoms, such evidence may include strongly positive biochemical test re-
sults (e.g., as illustrated in FIGURE 1) or, when results are not strongly positive,
repeated testing after ruling out causes of false-positive results. Imaging stud-
ies may be warranted in patients in whom the risk of pheochromocytoma is
high because of a hereditary predisposition or a previous history of the tumor,
even when biochemical evidence of a pheochromocytoma is less than com-
pelling. In some such patients, imaging studies may be appropriate as part of a
periodic surveillance plan, not only for pheochromocytoma, but also to check
for other tumors (e.g., kidney tumors in VHL syndrome).
Except for children and pregnant women or rarely in patients with allergies
to contrast medium, there was no consensus about whether to use computed
tomography (CT) or magnetic resonance imaging (MRI) for the initial local-
ization of a tumor. It was concluded that this depends largely on institutional
preference and expertise. Both imaging modalities have excellent sensitivity
for the detection of adrenal tumors, but lack adequate specificity for unequiv-
ocally confirming a mass as a pheochromocytoma. Neither CT nor MRI can
distinguish with clear certainty a functional from a nonfunctional tumor.
Overall, the sensitivity of contrast-enhanced CT in the localization of
pheochromocytoma is about 90–95%.35–37 Adrenal pheochromocytoma of
1 cm or larger or metastatic tumors at least 1.0–2.0 cm in size can be easily
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detected by CT using narrow collimation. CT densitometry using Hounsfield
units (HU) is helpful to distinguish between benign adrenal adenomas and other
tumors (often functioning) including metastatic lesions. Thus, a homogeneous
mass with a density measurement of less than 10 HU on an unenhanced CT is
almost certainly an adenoma. The appearance of homogeneity with soft-tissue
density (approximately 40–50 HU) and showing uniform enhancement follow-
ing intravenous injection of contrast medium is suggestive of a pheochromocy-
toma, but again it is important to note that it does not distinguish a functional
tumor from a nonfunctional one. Larger pheochromocytomas may undergo
hemorrhage or necrosis, which results in an inhomogeneous appearance both
before and after intravenous injection of contrast medium. Calcification occurs
in about 10–15% of cases.
The advantages of CT in the localization of pheochromocytoma are the
moderate cost and excellent detection of structures surrounding a pheochro-
mocytoma. Data from several different institutions suggest that new nonionic
contrast media do not pose a significant risk of a hypertensive crisis.38 Con-
sequently, several attendees indicated that they no longer use or recommend
-adrenoceptor blockade for such imaging. The recent development of mul-
tidetector computed tomography (MDCT) effectively allowing “volume” ac-
quisition of data using 16, 64, or even more detectors has revolutionized CT.
Images can now be acquired at great speed, viewed at very fine space intervals,
and reformatted to produce multiplanar or 3D images. This is likely to prove
useful, particularly in the identification of small and extra-adrenal tumors.
MRI is also widely used for the diagnosis of adrenal, extra-adrenal, or
metastatic pheochromocytoma and has similar sensitivity to CT.37,39 The hy-
pervascularity of pheochromocytomas characteristically makes them appear to
have a high or intermediate signal intensity on T2-weighted sequences.40 How-
ever, it should be noted that such intense signals can be elicited by hemorrhage
or hematomas, adenomas, and carcinomas, so an overlap with these tumors
and pheochromocytoma must be considered. Moreover, MRI is also a very
good imaging modality for the detection of extra-adrenal pheochromocytomas
such as intracardiac, juxtacardiac, and juxtavascular pheochromocytoma. This
is in part due to the superior contrast resolution of MRI, but also because of
the multiplanar acquisition of data without the need for reformatting. MRI can
be carried out with or without using intravenous contrast agents, and without
requiring -adrenergic blockade. MRI is the preferred initial imaging proce-
dure for pheochromocytoma in children, during pregnancy, or in patients with
known allergy to contrast agents.
Functional Imaging Studies
There is debate about whether functional imaging is necessary once a tu-
mor is located by CT or MRI. The functional imaging test of choice is
currently [123I]-metaiodobenzylguanidine (MIBG) scintigraphy,41,42 but as
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outlined above, several considerations may have an impact on the use of such
tests. Participants agreed that additional functional imaging studies should be
performed in most cases of biochemically proven pheochromocytoma for two
main reasons: (1) to prove that the tumor is indeed a pheochromocytoma; and
(2) to correctly detect any extension of disease that is not identified by anatomic
imaging (e.g., presence of multifocal or bilateral disease or metastatic lesions),
which may guide an appropriate therapeutic plan. It should be noted that this
recommendation was based on expert opinion, as data for or against the use of
routine functional imaging are limited. As reviewed by Dr. James Sisson (Uni-
versity of Michigan, Ann Arbor, MI), a unilateral lesion shown on CT or MRI
in the absence of a family history or any evidence of malignancy usually does
not reveal additional disease on [123I]-MIBG scintigraphy.43 Nevertheless, ex-
ceptions do occur and [123I]-MIBG scintigraphy may be specially useful when
the biochemical evidence for a pheochromocytoma is unequivocal, but CT or
MRI fails to identify the source.
Decisions for imaging should also take into account prior knowledge of
the patient. For example, in some patients at risk for extra-adrenal tumors
due to germline mutations of SDHB and succinate dehydrogenase D (SDHD)
genes or a previous history of paraganglioma, it may be appropriate to in-
clude [123I]-MIBG scintigraphy with CT or MRI as part of the initial imaging
evaluation. As indicated by Dr. Karel Pacak, exceptions where [123I]-MIBG
scintigraphy may not be necessary include solitary adrenal masses of less
than 5 cm associated with elevations of plasma or urinary epinephrine or its
metabolite, metanephrine. This suggestion was based on the perception that
malignant disease mainly occurs in association with large norepinephrine-
predominant tumors, as well as findings that practically all epinephrine-
producing pheochromocytomas—including those in patients with MEN 2—are
found in the adrenal gland or are recurrences of previously resected adrenal
tumors.34
Although no firm recommendations were directed to the use of other func-
tional imaging modalities, these should nevertheless be mentioned because
they hold considerable promise, and in certain situations they have already
been demonstrated to be of value in the localization of certain cases of the
tumor. Such functional positron emission tomography (PET) imaging ap-
proaches include use of several imaging agents: 6-[18F]-fluorodopamine, [18F]-
dihydroxyphenylalanine, [11C]-hydroxyephedrine, and [11C]epinephrine.44–48
All these imaging modalities are highly specific for pheochromocytoma be-
cause they depend on uptake into tumor cells by norepinephrine transporters or
other transport and storage mechanisms uniquely expressed in chromaffin tis-
sues, including pheochromocytoma tumor cells. Thus, positive results obtained
by these methods as well as [123I]-MIBG scintigraphy detect pheochromocy-
toma with almost 100% specificity.
[18F]-fluorodeoxyglucose ([18F]-FDG) PET scanning is another approach
used to localize pheochromocytoma. [18F]-FDG, however, is a nonspecific
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imaging agent with localization dependent on the higher metabolic rate of
tumors compared to surrounding normal tissue. Therefore, the use of this
imaging modality should be reserved for those patients in whom either
pheochromocytoma cannot be localized by other imaging methods or in pa-
tients with rapidly growing tumors that have a high metabolic rate, which often
results in excellent detection of those tumors. A disadvantage of PET is that
most of the radiopharmaceuticals (except FDG) are not widely available and
patients must be referred to a specialized medical center.
Another promising method to localize pheochromocytomas is somatostatin
receptor scintigraphy (“OctreoScan”).49,50 Although the method appears to
have limited use for the localization of solitary pheochromocytomas, it can be
useful in patients with metastatic disease or extra-adrenal paragangliomas.
Finally, some of those present at the breakout session indicated, in selected in-
stances, that venous catheterization and sampling studies may add information
not readily obtainable by other techniques.51 This would include sampling from
the adrenal veins in patients with elevated catecholamine or catecholamine
metabolites and in whom imaging studies have been uninformative, particu-
larly those with a background of hereditary disease. Reversal of the normally
high epinephrine-to-norepinephrine ratio in adrenal venous blood can be par-
ticularly useful in such cases for pointing to an intra-adrenal tumor.51 Measure-
ments of metanephrines in blood obtained during venous catheterization can
provide further advantages over measurements of the parent catecholamines.52
In summary, in most patients localization and confirmation of pheochro-
mocytoma should be attempted using at least two imaging modalities. It was
generally agreed that anatomical imaging studies (CT or MRI) should be com-
bined with functional (nuclear medicine) imaging studies for optimal local-
ization of primary, recurrent, multiple, or metastatic pheochromocytomas. CT
or MRI of the abdomen and pelvis should usually be used first and if they
are found to be negative, then CT or MRI of chest and neck and functional
imaging should follow. The functional imaging test of choice is [123I]-MIBG
scintigraphy, which may be further used to confirm a tumor as a pheochromo-
cytoma and to check for additional multifocal or malignant disease. If MIBG
scintigraphy is negative, the diagnosis should be reconsidered, particularly in
the light of drug-related false-positive results or the sleep apnea syndrome. Fur-
ther localization studies should be carried out in major centers and can include
PET with specific radiopharmaceuticals, octreotide scintigraphy, or selective
venous sampling. If suspicion of a poorly differentiated pheochromocytoma
remains, imaging with [18F]FDG PET may be appropriate.
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